COR Healthcare distribution · Large cap · Pharma supply chain · Specialty care · Thesis updated July 12, 2026

Cencora is stronger, but not cheap

Cencora is a key middleman in the drug supply chain, especially in U.S. pharmaceutical distribution.
Q2 FY2026 was better than expected, with adjusted EPS guidance raised to $17.65 to $17.90.
GLP-1 drugs are lifting sales, but they carry lower gross profit margins than many other products.
RCA and OneOncology add higher-margin physician services, which help offset pressure in the core business.
The main worries are debt, WBA customer concentration, and whether recent acquisitions can earn their keep.

01 Running thesis

A better setup, with a price question

Cencora has improved its near-term story. In Q2 FY2026, management raised full-year adjusted EPS guidance to $17.65 to $17.90 and restarted buybacks, with a goal of $1 billion in repurchases by the end of calendar 2026. That signals confidence in cash flow, but it also raises the bar for execution.

The bull case is simple. Cencora remains hard to replace in the U.S. drug market. It has huge scale, deep customer links, and rising GLP-1 volumes. At the same time, acquisitions like RCA and OneOncology are moving the company into higher-margin physician services, especially specialty care.

The bear case is also real. GLP-1 drugs add revenue but pressure margins. Manufacturer price cuts also hurt. Cencora has to keep finding profit in services and specialty distribution to offset that pressure.

This is not a clean bargain story. The company is performing better, but the balance sheet is more stretched after OneOncology, and the stock price needs earnings growth to show up on schedule. The next proof point is a full quarter of OneOncology results.

May 2026▲Cencora raised full-year adjusted EPS guidance to $17.65 to $17.90 and restarted buybacks, targeting $1 billion by the end of calendar 2026. Q2 results also showed U.S. operating income up 6% and International operating income up 14%.

May 2026▲The latest 10-Q showed OneOncology already helping U.S. gross profit margin, which rose 46 basis points in Q2 FY2026. That supports the idea that higher-margin physician services can offset lower-margin GLP-1 growth.

Feb 2026→Cencora announced the $4.6 billion cash acquisition of OneOncology, increasing its push into physician services. The strategy improved the growth case but also added debt and integration risk.

Nov 2025▼The fiscal 2025 10-K added uncertainty around WBA after its private equity acquisition. It also confirmed that Walgreens and Boots together accounted for about 25% of revenue in fiscal 2025.

Aug 2025→U.S. margins kept benefiting from RCA, while GLP-1 growth slowed from earlier levels. International profitability remained weak, keeping the turnaround question open.

May 2025→The first look at RCA was positive for U.S. margin, but International operating income fell 17.3%. The thesis became more balanced between services upside and overseas weakness.

Feb 2025▼Cencora showed clear GLP-1-driven margin pressure in the U.S. segment and closed its large RCA deal. The acquisition offered a fix, but it raised execution risk.

Nov 2024▼The fiscal 2024 10-K showed strong GLP-1 revenue growth but lower U.S. gross profit margin. WBA store closure plans and a PharmaLex impairment made the risk side more serious.

02 Business model

Moving medicines at huge scale

Cencora makes most of its money by buying medicines and healthcare products, then distributing them to pharmacies, health systems, doctors, and other healthcare providers. The business runs on very high sales volume and thin margins, so small changes in mix or pricing can matter a lot.

The U.S. Healthcare Solutions segment is the center of the company. In Q2 FY2026, it had $68.8 billion of revenue and operating income rose 6% year over year. Growth came from GLP-1 medications and specialty distribution, while manufacturer price reductions held it back.

International Healthcare Solutions is smaller but improving. In Q2 FY2026, revenue was $7.6 billion, up 13% as reported and 7% in constant currency. Operating income rose 14%, helped by European distribution and a recovery in specialty logistics.

Cencora is also pruning the business. Starting in fiscal 2026, it moved areas such as animal health and U.S. consulting services into an Other category while it reviews strategic alternatives. That could sharpen the company, but sales or write-downs could also expose weak assets.

03 Product portfolio

What flows through Cencora

Cash cow

Brand-name pharmaceuticals

These are patented drugs sold through Cencora’s large distribution network. They drive a large amount of revenue, but manufacturer price reductions can pressure profits.

Steady

Generic drugs and biosimilars

These are lower-cost versions of older medicines or biologic drugs. They help Cencora stay important to pharmacies and health systems as patents expire.

Growth engine

Specialty pharmaceuticals

These drugs often treat complex diseases and are used by hospitals and physician practices. Specialty distribution is one of the stronger parts of the U.S. segment.

Growth engine

GLP-1 diabetes and weight-loss drugs

GLP-1 products are adding major sales volume. In Q2 FY2026, U.S. GLP-1 sales rose by $1.9 billion, or 23%, from the prior year quarter, but these products have lower gross profit margins.

Option

Physician services platforms

RCA and OneOncology give Cencora more direct exposure to specialty physician practices. These businesses can lift margins, but they add integration risk.

Steady

Animal health products

Animal health is now in the Other category as Cencora reviews strategic alternatives. It still adds revenue, but it is no longer central to the main thesis.

Option

COVID-19 vaccines

COVID-19 vaccines can help margins when demand is strong. Recent filings show lower COVID vaccine sales have been one source of margin pressure.

04 Business segments

Where revenue comes from

U.S. Healthcare Solutions88%modest

International Healthcare Solutions10%growing fast

Other3%modest

Segment shares use Q2 FY2026 revenue before intersegment eliminations. U.S. Healthcare Solutions dominates the mix, and Walgreens and Boots together accounted for about 25% of fiscal 2025 revenue.

05 Risk factors

What could break the story

WBA relationship reset

High impact · Medium odds

Walgreens Boots Alliance and Boots together accounted for about 25% of Cencora revenue in fiscal 2025. WBA was acquired by Sycamore Partners in August 2025, and Cencora says the new owners may seek changes to WBA’s operations or to the relationship. That could affect volumes, pricing, or contract terms.

We watchAny new WBA distribution agreement, WBA store closure updates, or Cencora comments on customer volume.

Debt-funded OneOncology deal

High impact · Medium odds

Cencora acquired the majority of OneOncology on February 2, 2026. The Q2 10-Q lists total fair value consideration of $7.387 billion, including $4.649 billion of cash consideration, funded with new debt and cash on hand. If the business misses targets, leverage and investor trust could both suffer.

We watchOneOncology operating contribution, leverage ratios, integration costs, and management’s accretion comments.

Lower-margin GLP-1 mix

Medium impact · High odds

GLP-1 drugs are a growth driver, but Cencora says they have lower gross profit margins. In Q2 FY2026, U.S. Healthcare Solutions gross profit margin still rose 46 basis points because OneOncology helped offset that pressure. If GLP-1s keep outgrowing higher-margin areas, margin gains may fade.

We watchU.S. gross profit margin, GLP-1 sales growth, and comments on manufacturer price reductions.

International rebound fades

Medium impact · Medium odds

International Healthcare Solutions improved in Q2 FY2026, with operating income up 14% year over year. That was a reversal from earlier weakness in specialty logistics and consulting. One good quarter helps, but the long-term margin profile is still an open question.

We watchInternational operating income growth and constant-currency revenue growth over the next two quarters.

Non-core asset write-downs

Medium impact · Medium odds

Cencora has already recorded major impairments, including a $723.9 million full-year goodwill impairment for PharmaLex and a $249.5 million impairment tied to U.S. Consulting Services in Q1 FY2026. More asset sales could clarify the company, but low sale prices would hurt reported results and signal past deal mistakes.

We watchUpdates on strategic alternatives for Other assets, sale proceeds, and any new impairment charges.

06 Quick answers

In one breath

What does Cencora actually do?

Cencora distributes medicines and healthcare products to pharmacies, hospitals, doctors, and other providers. It also offers services around specialty drugs, physician practices, and global commercialization.

Why do GLP-1 drugs matter for Cencora?

GLP-1 drugs for diabetes and weight loss are driving large sales growth through Cencora’s network. The catch is that Cencora says these products carry lower gross profit margins, so revenue growth does not fully translate into profit growth.

Why did Cencora buy OneOncology?

OneOncology gives Cencora deeper ties to community oncology practices. The goal is to add higher-margin services and strengthen Cencora’s position in specialty pharmaceuticals.

What is the biggest customer risk?

WBA is the key risk because Walgreens and Boots together were about 25% of fiscal 2025 revenue. New private equity ownership adds uncertainty around store closures, contract terms, pricing, and volume.